Supplementary Table 4. Baseline characteristics of metformin users and non-users after propensity score matching in women

Variable	Women		*p* value
	Metformin users (n = 1,924)	Metformin non-users (n = 1,924)	
Age group (yr)			> 0.999
18–24	1 (0.1)	1 (0.1)	
25–34	6 (0.3)	6 (0.3)	
35–44	39 (2.0)	39 (2.0)	
45–54	103 (5.4)	103 (5.4)	
55–64	178 (9.3)	178 (9.3)	
65–74	500 (26.0)	500 (26.0)	
> 75	1,097 (57.0)	1,097 (57.0)	
Age (yr)	76 (69–81)	76 (69–81)	> 0.999
Region, metropolitan	53 (39.1)	784 (40.8)	0.31
Nationality, Korean	1,914 (99.5)	1,916 (99.6)	0.64
Household income			0.63
0 (lowest)	233 (12.1)	243 (12.6)	
1	311 (16.2)	295 (15.3)	
2	185 (9.6)	208 (10.8)	
3	258 (13.4)	255 (13.3)	
4	317 (16.5)	336 (17.5)	
5 (highest)	620 (32.2)	587 (30.5)	
Disability			< 0.01
No	1,636 (85.0)	1,512 (78.6)	
Physical disability	280 (14.6)	399 (20.7)	
Internal disability	8 (0.4)	13 (0.7)	
Lesion site of TB			0.03
Pulmonary	1,652 (85.9)	1,603 (83.3)	
Extra-pulmonary	272 (14.1)	321 (16.7)	
TB history			0.64
New case	1,771 (92.1)	1,763 (91.6)	
Previously treated TB	153 (8.0)	161 (8.4)	
PPM hospital	1,442 (75.0)	1,469 (76.4)	0.31
AFB smear positivity	721 (37.5)	660 (34.3)	0.12
Culture positivity	951 (49.4)	895 (46.5)	0.19
Charlson Comorbidity Index			> 0.999
0	435 (22.6)	435 (22.6)	
1	861 (44.8)	861 (44.8)	
2	136 (7.1)	136 (7.1)	
≥ 3	492 (25.6)	492 (25.6)	
Comorbidity			
Transplantation	3 (0.2)	8 (0.4)	0.23
HIV	0 (0.0)	0 (0.0)	
Cancer	34 (1.8)	44 (2.3)	0.25

Supplementary Table 4. Continued

Variable	Women		p value
	Metformin users (n = 1,924)	Metformin non-users (n = 1,924)	
Notification year			> 0.999
2011	288 (15.0)	295 (15.3)	
2012	271 (14.1)	267 (13.9)	
2013	227 (11.8)	224 (11.6)	
2014	298 (15.5)	297 (15.4)	
2015	282 (14.7)	283 (14.7)	
2016	280 (14.6)	280 (14.6)	
2017	278 (14.4)	278 (14.5)	
Anti-diabetic treatment			
Sulfonylurea	1,069 (55.6)	1,166 (60.6)	< 0.01
Insulin	82 (4.3)	178 (9.3)	< 0.01
Other DM medication[a]	1,150 (59.8)	1,213 (63.1)	0.04
Follow-up duration (d)	212 (183–283)	214 (182–286)	0.78
Treatment outcome			0.01
Treatment success/failure	1,728 (89.8)	1,672 (86.9)	
Death due to all causes	196 (10.2)	252 (13.1)	
Cause of death			0.37
TB-related deaths	45 (2.3)	49 (2.6)	
Non-TB-related deaths	151 (7.9)	203 (10.6)	

Values are presented as number (%) or median (interquartile range).

AFB, acid-fast bacilli; DM, diabetes mellitus; HIV, human immunodeficiency virus; PPM, public-private mix; TB, tuberculosis.

[a]Other DM medications include dipeptidyl peptidase–4 inhibitors, glinide, thiazolidinedione, glucagon-like peptide-1, alpha-glucosidase inhibitors, and sodium-glucose cotransporter-2 inhibitors.